GlassScriptPhysician profile
Lynn A Weston
NPI 1053482000
$16,666.20
in general payments reported to CMS, 2019-2025
28 companies · $4,428 in 2025
The $4,428 reported for 2025 was more than what 87% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,511 · 2020: $1,176 · 2021: $18.44 · 2022: $3,165 · 2023: $84.20 · 2024: $283 · 2025: $4,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,078 · Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,077.82 |
| Food and Beverage | $718.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $15,540.62 | 2019-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $222.16 | 2021-2025 | Signia, Sonicision |
| Davol INC. | $172.35 | 2019-2024 | Phasix Mesh |
| Prescient Surgical | $126.72 | 2019 | |
| Tela Bio, INC. | $49.91 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $46.35 | 2019-2020 | |
| Convatec INC. | $45.42 | 2020-2022 | |
| Celgene Corporation | $39.05 | 2019 | |
| Ethicon US, LLC | $38.63 | 2019 | |
| Histosonics, INC. | $35.07 | 2024 | |
| Merck Sharp & Dohme LLC | $34.11 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $30.10 | 2019 | |
| Deciphera Pharmaceuticals INC. | $28.74 | 2024 | Qinlock |
| Covidien LP | $24.88 | 2020 | |
| Amag Pharmaceuticals, INC. | $21.40 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.64 | 2019 | |
| Eisai INC. | $19.03 | 2019 | |
| Misonix INC | $18.54 | 2019 | |
| Incyte Corporation | $18.23 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $17.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2019 | |
| Genzyme Corporation | $15.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.79 | 2020 | |
| West Therapeutics Development, LLC | $14.03 | 2019 | |
| Array Biopharma INC | $13.63 | 2019 | |
| Advanced Accelerator Applications | $12.66 | 2020 | |
| Medtronic USA, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.